KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Non-Current Assets: 2009-2024

Historic Non-Current Assets for Teva Pharmaceutical Industries (TEVA) over the last 16 years, with Dec 2024 value amounting to $26.8 billion.

  • Teva Pharmaceutical Industries' Non-Current Assets fell 7.89% to $27.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $27.1 billion, marking a year-over-year decrease of 7.89%. This contributed to the annual value of $26.8 billion for FY2024, which is 13.62% down from last year.
  • As of FY2024, Teva Pharmaceutical Industries' Non-Current Assets stood at $26.8 billion, which was down 13.62% from $31.0 billion recorded in FY2023.
  • In the past 5 years, Teva Pharmaceutical Industries' Non-Current Assets registered a high of $37.6 billion during FY2020, and its lowest value of $26.8 billion during FY2024.
  • Moreover, its 3-year median value for Non-Current Assets was $31.0 billion (2023), whereas its average is $29.9 billion.
  • Data for Teva Pharmaceutical Industries' Non-Current Assets shows a maximum YoY fell of 14.48% (in 2020) over the last 5 years.
  • Teva Pharmaceutical Industries' Non-Current Assets (Yearly) stood at $37.6 billion in 2020, then decreased by 6.75% to $35.1 billion in 2021, then dropped by 8.93% to $32.0 billion in 2022, then declined by 3.02% to $31.0 billion in 2023, then decreased by 13.62% to $26.8 billion in 2024.